Bioxytran (BIXT) Enterprise Value (2011 - 2026)
Bioxytran (BIXT) posted Enterprise Value of -$463047.0 for Q1 2026, up 9.19% sequentially from -$509914.0 in Q4 2025, and down 10549.66% YoY from N/an in Q1 2025.
Bioxytran (BIXT) Enterprise Value (2011 - 2026) Analysis & Trends
Bioxytran has reported Enterprise Value for 16 years, with the latest figure at -$463047.0 in Q1 2026.
- Quarterly Enterprise Value fell 10549.66% year-over-year to -$463047.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$463047.0 (down 10549.66% YoY) and the FY2025 annual result came in at -$509914.0, down 9793.56% from the prior year.
- Enterprise Value climbed to -$463047.0 in Q1 2026 per BIXT's latest filing, from -$509914.0 in the prior quarter.
- Over five years, Enterprise Value peaked at -$3144.0 in Q2 2025 and troughed at -$1.2 million in Q1 2022.
- A 5-year average of -$519309.6 and a median of -$669467.0 in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 99.56% in 2025, then plunged 10549.66% in 2026.
- Over 5 years, Enterprise Value stood at -$886029.0 in 2022, then climbed by 20.21% to -$706972.0 in 2023, then jumped by 99.27% to -$5154.0 in 2024, then sank by 9793.56% to -$509914.0 in 2025, then grew by 9.19% to -$463047.0 in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$463047.0, -$509914.0, and -$14499.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -250,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -463,047.00 |
| Dec 31, 2025 | -509,914.00 |
| Sep 30, 2025 | -14,499.00 |
| Jun 30, 2025 | -3,144.00 |
| Mar 31, 2025 | -4,348.00 |
| Dec 31, 2024 | -5,154.00 |
| Sep 30, 2024 | -34,672.00 |
| Jun 30, 2024 | -707,732.00 |
| Mar 31, 2024 | -704,234.00 |
| Dec 31, 2023 | -706,972.00 |
| Sep 30, 2023 | -739,336.00 |
| Jun 30, 2023 | -669,467.00 |
| Mar 31, 2023 | -777,323.00 |
| Dec 31, 2022 | -886,029.00 |
| Sep 30, 2022 | -913,760.00 |
| Jun 30, 2022 | -500,677.00 |
| Mar 31, 2022 | -1.19 Mn |
| Dec 31, 2021 | -469,614.00 |
| Sep 30, 2021 | 708,468.00 |
| Jun 30, 2021 | 698,949.00 |